CN113412275A - 用于癌症免疫疗法的基于迷路蛋白的肽及其用途 - Google Patents

用于癌症免疫疗法的基于迷路蛋白的肽及其用途 Download PDF

Info

Publication number
CN113412275A
CN113412275A CN201980091552.9A CN201980091552A CN113412275A CN 113412275 A CN113412275 A CN 113412275A CN 201980091552 A CN201980091552 A CN 201980091552A CN 113412275 A CN113412275 A CN 113412275A
Authority
CN
China
Prior art keywords
seq
peptide
amino acids
similarity
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980091552.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·拉多舍维奇
M·巴比奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leipzig Immunotherapy Usa Co ltd
Original Assignee
Leipzig Immunotherapy Usa Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leipzig Immunotherapy Usa Co ltd filed Critical Leipzig Immunotherapy Usa Co ltd
Publication of CN113412275A publication Critical patent/CN113412275A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980091552.9A 2018-12-13 2019-12-13 用于癌症免疫疗法的基于迷路蛋白的肽及其用途 Pending CN113412275A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779377P 2018-12-13 2018-12-13
US62/779,377 2018-12-13
PCT/US2019/066264 WO2020123964A1 (en) 2018-12-13 2019-12-13 Labyrinthin-based peptides for cancer immunotherapies and uses thereof

Publications (1)

Publication Number Publication Date
CN113412275A true CN113412275A (zh) 2021-09-17

Family

ID=71077093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980091552.9A Pending CN113412275A (zh) 2018-12-13 2019-12-13 用于癌症免疫疗法的基于迷路蛋白的肽及其用途

Country Status (11)

Country Link
US (1) US20220409709A1 (https=)
EP (1) EP3894432A4 (https=)
JP (2) JP2022513913A (https=)
KR (2) KR20260042221A (https=)
CN (1) CN113412275A (https=)
AU (1) AU2019397539B2 (https=)
CA (1) CA3123396A1 (https=)
IL (1) IL283933A (https=)
MX (1) MX2021007074A (https=)
TW (1) TW202039536A (https=)
WO (1) WO2020123964A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143868A (zh) * 2023-01-10 2023-05-23 合肥工业大学 一种能够增强咸味的多肽及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301302A (zh) * 1998-03-17 2001-06-27 詹姆斯·A·拉多舍维奇 编码癌症标记迷路蛋白的基因
US20030021798A1 (en) * 1999-04-12 2003-01-30 Immtech International Inc. Use of mCRP to enhance immune responses
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof
US20150274787A1 (en) * 2011-12-21 2015-10-01 Sanofi Method for recombinant production of labyrinthopeptins and functional derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
ATE536370T1 (de) * 2006-02-02 2011-12-15 Univ Alabama Res Found Nicht gespulte schutzregionen der pneumokokken- oberflächenproteine pspa und pspc
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
US20200190480A1 (en) * 2017-08-30 2020-06-18 Next Pharma Inc. ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301302A (zh) * 1998-03-17 2001-06-27 詹姆斯·A·拉多舍维奇 编码癌症标记迷路蛋白的基因
US20030021798A1 (en) * 1999-04-12 2003-01-30 Immtech International Inc. Use of mCRP to enhance immune responses
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof
US20150274787A1 (en) * 2011-12-21 2015-10-01 Sanofi Method for recombinant production of labyrinthopeptins and functional derivatives thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张根葆等: "《基础医学概论 第2版》", 28 February 2018, 中国科学技术大学出版社, pages: 401 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143868A (zh) * 2023-01-10 2023-05-23 合肥工业大学 一种能够增强咸味的多肽及其应用
CN116143868B (zh) * 2023-01-10 2025-10-21 合肥工业大学 一种能够增强咸味的多肽及其应用

Also Published As

Publication number Publication date
JP2022513913A (ja) 2022-02-09
IL283933A (en) 2021-07-29
KR102929753B1 (ko) 2026-02-24
AU2019397539A1 (en) 2021-07-15
EP3894432A4 (en) 2023-01-25
KR20260042221A (ko) 2026-03-30
CA3123396A1 (en) 2020-06-18
WO2020123964A1 (en) 2020-06-18
US20220409709A1 (en) 2022-12-29
JP2025072379A (ja) 2025-05-09
AU2019397539B2 (en) 2025-04-24
MX2021007074A (es) 2021-10-13
EP3894432A1 (en) 2021-10-20
TW202039536A (zh) 2020-11-01
KR20210131995A (ko) 2021-11-03

Similar Documents

Publication Publication Date Title
O'Boyle et al. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn
JP2022088665A (ja) がんの治療
JP2018538265A (ja) 癌を治療するための方法及び組成物
CN105816867A (zh) 预防乳腺癌复发的疫苗
JP2024109648A (ja) ネオエピトープを標的とするワクチン
TW201704267A (zh) 用於治療癌症的免疫性融合蛋白
Gerard et al. A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors
Pifferi et al. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen
CN101171032B (zh) 天然肽及其优化的衍生物作为疫苗的应用
US10105427B2 (en) Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
JP2025072379A (ja) がん免疫療法のためのラビリンチンベースのペプチドとその使用
JP6385280B2 (ja) 自家癌細胞ワクチン
JP6957448B2 (ja) ワクチン組成物およびその使用
RU2607379C2 (ru) Раковый антиген
JP6421208B2 (ja) がん抗原
US20240091328A1 (en) Formulations and methods for mhc-i restricted epitope immunization
CN121668290A (zh) 一种基于肿瘤-视网膜抗原的mRNA疫苗及其应用
EA037056B1 (ru) Ксеногенные вакцины, полученные из здоровых тканей, для преодоления иммунной толерантности в отношении опухолеассоциированных антигенов
Scott Recombinant NY-ESO-1 Protein With ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses In Humans
CN114630837A (zh) 抗原性多肽及其使用方法
KR20220010712A (ko) Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법
WO2017176784A1 (en) Adenocarcinoma antigenic determinants and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination